Founded in 2000, Celator® Pharmaceuticals is developing advanced therapies to treat cancer. Based on a proprietary technology platform, research at Celator identifies synergistic ratios of drugs to improve tumor cell kill and locks the synergistic ratio in a drug delivery vehicle to maintain the ratio in patients. The goal of this approach is to improve the therapeutic benefit these drugs provide patients.
Many forms of cancer are currently treated with drug regimens that combine individual chemotherapeutic drugs. Because many drugs are toxic at certain levels, these “cocktails” are typically developed by combining drugs that have non-overlapping toxicity profiles and different mechanisms of action. In this way, individual drugs can be combined at their maximum dosing levels. This approach has represented the standard of care in oncology for decades.
By focusing only on the impact of individual drugs, this standard has failed to recognize the critical role that drug ratios play in the effectiveness of combining chemotherapies. Research efforts led by Celator have shown that many combinations of chemotherapeutic drugs can act synergistically to kill cancer cells when combined and maintained at certain ratios. These same agents, when combined at other ratios can act antagonistically or with reduced clinical benefit. Celator’s research and clinical development programs are based on the finding that the ratios used to create these drug regimens – and the ability to control those ratios systemically – can have a profound impact on their efficacy.
Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the company will host an Analyst and Investor Day on Thursday, July...
The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML
– This is part of the existing $5 Million Therapy Acceleration Program partnership – – Accelerated payment based on recently reported positive induction response rate – Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that The Leukemia & Lymphoma Society® (LLS) is...
Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
CPX-351 demonstrates a 43.2% relative improvement in induction response rate Conference call today at 8:30am Eastern Time to discuss the results Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with...
– Encouraging response rate achieved; including patients with high-risk (secondary) AML (the Phase 3 study population), de novo AML, relapsed AML, and relapsed ALL – Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination...